Search Results - takashi+tsukamoto

5 Results

Sort By:

Dendrimer Conjugated Glutamine Antagonists for Targeted Brain and Tumor Delivery

Value Proposition· Deliver glutamine antagonists to the CNS without GI and systemic toxicity assiated with free DON.· High specificity for activated microglia and tumor-associated macrophages, providing therapeutic precision across neuroinflammatory and oncologic indications. · Broad applicability across CNS, cancer, and immune disorders,...

Published: 3/13/2026 | Inventor(s): Barbara Slusher, Rana Rais, Kannan Rangaramanujam, Anjali Sharma, Pavel Majer, Benjamin Bell, Lukas Tenora, Katerina Novotna, Martin Hadzima, Martin Kaiser, Tomas Tichy, Takashi Tsukamoto, Run-Duo Gao, Xiaolei Zhu

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

New Therapeutic Approach for the Treatment of Neuropathic Pain

Unmet NeedChronic pain affects around 50-million adults within the United States (see CDC). Currently the dominant treatment option for moderate to severe pain are opioids, which have a range of associated adverse effects as well as the potential for abuse. Despite the development of abuse-deterrent formulations, opioid dependence remains a major challenge....

Published: 3/13/2026 | Inventor(s): Takashi Tsukamoto, Barbara Slusher, Niyada Hin, Camilo Rojas, Xinzhong Dong, Yun Guan, Ilyas Berhane

Keywords(s): Agonists/Promoters, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Pain > Chronic Neuropathic Pain, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules

Small Molecule Neutral Sphingomyelinase 2 (nSMase2) Inhibitors

Unmet NeedNeutral sphingomyelinase 2 (nSMase2) is expressed in neurons and hydrolyzes sphingomyelin, producing the lipid ceramide, which functions in stress responses leading to apoptosis, cell growth arrest, and differentiation. Increased levels of ceramides have been associated with many neurological disorders, including Alzheimer’s disease, multiple...

Published: 3/13/2026 | Inventor(s): Takashi Tsukamoto, Niyada Hin, Ondrej Stepanek, Barbara Slusher, Camilo Rojas, Ajit Thomas

Keywords(s): Antagonists/Inhibitors, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules

DOPA and Caffeic Acid Analogs as Novel GCPII Inhibitors

Unmet NeedGlutamate is the primary excitatory neurotransmitter in the human brain [1]. Excessive glutamate signaling can disrupt calcium homeostasis, leading to mitochondrial dysfunction, the overproduction of reactive oxygen species, and neuron loss via necrotic or apoptotic pathways [2]. This phenomenon, known as excitotoxicity, contributes to disease...

Published: 3/13/2026 | Inventor(s): Barbara Slusher, Rana Rais, Takashi Tsukamoto

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Technology Classifications, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for Cancer Therapy

Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for cancer therapyJHU REF: C13142 Invention novelty: An improved glutaminase (GLS) inhibitors delivery system to enhance efficacy and prolong glutaminase inhibitor drug levels in tumor for improve treatment of pancreatic cancer. Value Proposition: Currently available glutaminase inhibitors...

Published: 3/12/2026 | Inventor(s): Barbara Slusher, Jie Fu, Justin Hanes, Qingguo Xu, Quy Hoa Le Thi, Takashi Tsukamoto

Keywords(s): Adenocarcinoma, Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Non-novel, Off-the-shelf, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities